Difference between revisions of "Acute myeloid leukemia"
m |
m |
||
Line 13: | Line 13: | ||
==ELN== | ==ELN== | ||
====Current==== | ====Current==== | ||
− | *[http://www.bloodjournal.org/content/129/4/424.long Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2017)] [https://www.ncbi.nlm.nih.gov/pubmed/27895058 PubMed] | + | *[http://www.bloodjournal.org/content/129/4/424.long Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2017)] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291965/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27895058 PubMed] |
====Older==== | ====Older==== | ||
*[http://www.bloodjournal.org/content/115/3/453.long Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet (2010)] [https://www.ncbi.nlm.nih.gov/pubmed/19880497 PubMed] | *[http://www.bloodjournal.org/content/115/3/453.long Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet (2010)] [https://www.ncbi.nlm.nih.gov/pubmed/19880497 PubMed] | ||
Line 157: | Line 157: | ||
|style="background-color:#eeee00"|Seems not superior | |style="background-color:#eeee00"|Seems not superior | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480917/ Fernandez et al. 2009 (ECOG E1900)] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|7+3d (high-dose) | |7+3d (high-dose) | ||
Line 256: | Line 256: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480917/ Fernandez et al. 2009 (ECOG E1900)] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|7+3d, standard-dose dauno | |7+3d, standard-dose dauno | ||
|style="background-color:#00cd00"|Superior OS | |style="background-color:#00cd00"|Superior OS | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ Zeidner et al. 2015] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[Acute_myeloid_leukemia#FLAM|FLAM]] | |[[Acute_myeloid_leukemia#FLAM|FLAM]] | ||
Line 326: | Line 326: | ||
# Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. [http://www.nature.com/leu/journal/v18/n5/full/2403336a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14999298 PubMed] | # Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. [http://www.nature.com/leu/journal/v18/n5/full/2403336a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14999298 PubMed] | ||
# Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1235-48. Erratum in: N Engl J Med. 2010 Mar 25;362(12):1155. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text. [http://www.nejm.org/doi/full/10.1056/NEJMoa0901409 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19776405 PubMed] | # Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1235-48. Erratum in: N Engl J Med. 2010 Mar 25;362(12):1155. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text. [http://www.nejm.org/doi/full/10.1056/NEJMoa0901409 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19776405 PubMed] | ||
− | # Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59. [http://www.nejm.org/doi/full/10.1056/NEJMoa0904544 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19776406 PubMed] | + | # Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59. [http://www.nejm.org/doi/full/10.1056/NEJMoa0904544 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480917/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19776406 PubMed] |
− | ## '''Update:''' Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8. Epub 2016 Jan 11. [http://www.bloodjournal.org/content/127/12/1551.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26755712 PubMed] | + | ## '''Update:''' Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8. Epub 2016 Jan 11. [http://www.bloodjournal.org/content/127/12/1551.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807422/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26755712 PubMed] |
# Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. [http://jco.ascopubs.org/content/30/20/2441.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22508825 PubMed] | # Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. [http://jco.ascopubs.org/content/30/20/2441.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22508825 PubMed] | ||
# Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16. Epub 2012 Apr 5. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60485-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22482940 PubMed] | # Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16. Epub 2012 Apr 5. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60485-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22482940 PubMed] | ||
Line 333: | Line 333: | ||
# Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013 Sep 1;31(25):3110-8. Epub 2013 Jul 29. [http://ascopubs.org/doi/abs/10.1200/JCO.2012.46.4990 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23897964 PubMed] | # Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013 Sep 1;31(25):3110-8. Epub 2013 Jul 29. [http://ascopubs.org/doi/abs/10.1200/JCO.2012.46.4990 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23897964 PubMed] | ||
# Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Epub 2013 Aug 12. [http://jco.ascopubs.org/content/31/27/3360.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23940227 PubMed] | # Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Epub 2013 Aug 12. [http://jco.ascopubs.org/content/31/27/3360.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23940227 PubMed] | ||
− | # Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878-85. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/25/3878.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25833957 PubMed] | + | # Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878-85. Epub 2015 Apr 1. [http://www.bloodjournal.org/content/125/25/3878.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505010/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25833957 PubMed] |
# Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10;33(11):1252-7. Epub 2015 Mar 2. [http://jco.ascopubs.org/content/33/11/1252.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732165 PubMed] | # Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10;33(11):1252-7. Epub 2015 Mar 2. [http://jco.ascopubs.org/content/33/11/1252.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25732165 PubMed] | ||
− | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] | + | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] |
− | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] | + | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] |
# Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015 Dec;16(16):1691-9. Epub 2015 Nov 6. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00362-9/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26549589 PubMed] | # Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015 Dec;16(16):1691-9. Epub 2015 Nov 6. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00362-9/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26549589 PubMed] | ||
# Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017 | # Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017 | ||
− | Feb;31(2):310-317. Epub 2016 Sep 2. [http://www.nature.com/leu/journal/v31/n2/fig_tab/leu2016225f1.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27624670 PubMed] | + | Feb;31(2):310-317. Epub 2016 Sep 2. [http://www.nature.com/leu/journal/v31/n2/fig_tab/leu2016225f1.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292678/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27624670 PubMed] |
==Cytarabine, Daunorubicin, Midostaurin {{#subobject:b7ea7e|Regimen=1}}== | ==Cytarabine, Daunorubicin, Midostaurin {{#subobject:b7ea7e|Regimen=1}}== | ||
Line 467: | Line 467: | ||
# Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004 Jan 15;103(2):479-85. Epub 2003 Sep 25. [http://www.bloodjournal.org/content/103/2/479.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14512295 PubMed] | # Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004 Jan 15;103(2):479-85. Epub 2003 Sep 25. [http://www.bloodjournal.org/content/103/2/479.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14512295 PubMed] | ||
# Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010 Feb 10;28(5):808-14. Epub 2010 Jan 4. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.2652 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20048183 PubMed] | # Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010 Feb 10;28(5):808-14. Epub 2010 Jan 4. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.2652 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20048183 PubMed] | ||
− | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] | + | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] |
# Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017 Mar 23;129(12):1636-1645. Epub 2017 Jan 3. [http://www.bloodjournal.org/content/129/12/1636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28049642 PubMed] | # Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017 Mar 23;129(12):1636-1645. Epub 2017 Jan 3. [http://www.bloodjournal.org/content/129/12/1636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28049642 PubMed] | ||
Line 491: | Line 491: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ Ravandi et al. 2010] |
|style="background-color:#eeee00"|Phase I/II | |style="background-color:#eeee00"|Phase I/II | ||
|- | |- | ||
Line 499: | Line 499: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cytarabine (Cytosar)]] 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose: 6000 mg/m<sup>2</sup>) | *[[Cytarabine (Cytosar)]] 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 4 (total dose: 6000 mg/m<sup>2</sup>) | ||
− | **Patients older than 60 received: | + | **Patients older than 60 received: 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 3 (total dose: 4500 mg/m<sup>2</sup>) |
*[[Idarubicin (Idamycin)]] 12 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 3 | *[[Idarubicin (Idamycin)]] 12 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 3 | ||
*[[Sorafenib (Nexavar)]] 400 mg PO BID on days 1 to 7 | *[[Sorafenib (Nexavar)]] 400 mg PO BID on days 1 to 7 | ||
Line 509: | Line 509: | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
− | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] | + | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] |
− | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] | + | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091714/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] |
==Cytarabine, Idarubicin, Vorinostat {{#subobject:1c76f3|Regimen=1}}== | ==Cytarabine, Idarubicin, Vorinostat {{#subobject:1c76f3|Regimen=1}}== | ||
Line 523: | Line 523: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ Garcia-Manero et al. 2012] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 529: | Line 529: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cytarabine (Cytosar)]] 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 4 to 7 (total dose: 6000 mg/m<sup>2</sup>) | *[[Cytarabine (Cytosar)]] 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 4 to 7 (total dose: 6000 mg/m<sup>2</sup>) | ||
− | **Patients older than 60 received: | + | **Patients older than 60 received: 1500 mg/m<sup>2</sup>/day IV continuous infusion on days 4 to 6 (total dose: 4500 mg/m<sup>2</sup>) |
*[[Idarubicin (Idamycin)]] 12 mg/m<sup>2</sup> IV once per day on days 4 to 6 | *[[Idarubicin (Idamycin)]] 12 mg/m<sup>2</sup> IV once per day on days 4 to 6 | ||
*[[Vorinostat (Zolinza)]] 500 mg PO TID on days 1 to 3 | *[[Vorinostat (Zolinza)]] 500 mg PO TID on days 1 to 3 | ||
Line 542: | Line 542: | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
− | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] | + | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] |
==Cytarabine & Mitoxantrone {{#subobject:240c72|Regimen=1}}== | ==Cytarabine & Mitoxantrone {{#subobject:240c72|Regimen=1}}== | ||
Line 643: | Line 643: | ||
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 2 to 6 | *[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 2 to 6 | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 6, given 4 hours after [[Fludarabine (Fludara)]] | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 6, given 4 hours after [[Fludarabine (Fludara)]] | ||
− | *[[Lenograstim (Granocyte)]] 263 | + | *[[Lenograstim (Granocyte)]] 263 mcg SC once per day on days 1 to 7 |
*[[Idarubicin (Idamycin)]] 8 mg/m<sup>2</sup> IV once per day on days 4 to 6 | *[[Idarubicin (Idamycin)]] 8 mg/m<sup>2</sup> IV once per day on days 4 to 6 | ||
Line 664: | Line 664: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ Zeidner et al. 2015] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[#Cytarabine_.26_Daunorubicin|7+3d, high-dose dauno]] | |[[#Cytarabine_.26_Daunorubicin|7+3d, high-dose dauno]] | ||
Line 678: | Line 678: | ||
===References=== | ===References=== | ||
− | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] | + | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] |
==MICE {{#subobject:324735|Regimen=1}}== | ==MICE {{#subobject:324735|Regimen=1}}== | ||
Line 724: | Line 724: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591761/ Ocio et al. 2015 (panobidara)] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 740: | Line 740: | ||
===References=== | ===References=== | ||
− | # Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. [http://www.haematologica.org/content/100/10/1294 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26160880 PubMed] | + | # Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. [http://www.haematologica.org/content/100/10/1294 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591761/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26160880 PubMed] |
==Azacitidine (Vidaza) {{#subobject:791718|Regimen=1}}== | ==Azacitidine (Vidaza) {{#subobject:791718|Regimen=1}}== | ||
Line 754: | Line 754: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ Dombret et al. 2015] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#7.2B3d_.28.22standard.22_or_.22conventional.22_dose.29|7+3d]]<br> [[Acute_myeloid_leukemia#7.2B3i|7+3i]]<br> [[Acute_myeloid_leukemia#Best_supportive_care|Best supportive care]]<br> [[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29|Cytarabine]] | |[[Acute_myeloid_leukemia#7.2B3d_.28.22standard.22_or_.22conventional.22_dose.29|7+3d]]<br> [[Acute_myeloid_leukemia#7.2B3i|7+3i]]<br> [[Acute_myeloid_leukemia#Best_supportive_care|Best supportive care]]<br> [[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29|Cytarabine]] | ||
Line 766: | Line 766: | ||
===References=== | ===References=== | ||
− | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] | + | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] |
==Best supportive care== | ==Best supportive care== | ||
Line 780: | Line 780: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ Kantarjian et al. 2012] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Decitabine_.28Dacogen.29|Decitabine]] | |[[Acute_myeloid_leukemia#Decitabine_.28Dacogen.29|Decitabine]] | ||
|style="background-color:#ff0000"|Might have inferior OS | |style="background-color:#ff0000"|Might have inferior OS | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ Dombret et al. 2015] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Azacitidine_.28Vidaza.29|Azacitidine]] | |[[Acute_myeloid_leukemia#Azacitidine_.28Vidaza.29|Azacitidine]] | ||
Line 800: | Line 800: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | <!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | ||
− | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] | + | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] |
− | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] | + | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] |
<!-- Presented in part at the 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | <!-- Presented in part at the 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | ||
# Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016 Mar 20;34(9):972-9. Epub 2016 Jan 25. [http://jco.ascopubs.org/content/34/9/972.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26811524 PubMed] | # Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016 Mar 20;34(9):972-9. Epub 2016 Jan 25. [http://jco.ascopubs.org/content/34/9/972.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26811524 PubMed] | ||
Line 817: | Line 817: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081352/ Faderl et al. 2008] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[#Clofarabine_.26_Cytarabine|Clofarabine & Cytarabine]] | |[[#Clofarabine_.26_Cytarabine|Clofarabine & Cytarabine]] | ||
Line 836: | Line 836: | ||
===References=== | ===References=== | ||
− | # Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. [http://www.bloodjournal.org/content/112/5/1638.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18565853 PubMed] | + | # Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. [http://www.bloodjournal.org/content/112/5/1638.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081352/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18565853 PubMed] |
# Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010 May 10;28(14):2389-95. Epub 2010 Apr 12. [http://ascopubs.org/doi/abs/10.1200/JCO.2009.26.4242 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20385984 PubMed] | # Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010 May 10;28(14):2389-95. Epub 2010 Apr 12. [http://ascopubs.org/doi/abs/10.1200/JCO.2009.26.4242 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20385984 PubMed] | ||
Line 851: | Line 851: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081352/ Faderl et al. 2008] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[#Clofarabine_.28Clolar.29|Clofarabine]] | |[[#Clofarabine_.28Clolar.29|Clofarabine]] | ||
Line 870: | Line 870: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907176/ Faderl et al. 2010] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 883: | Line 883: | ||
===References=== | ===References=== | ||
− | # Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. [http://www.bloodjournal.org/content/112/5/1638.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18565853 PubMed] | + | # Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. [http://www.bloodjournal.org/content/112/5/1638.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081352/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18565853 PubMed] |
− | # Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27429/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22282348 PubMed] | + | # Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27429/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22282348 PubMed] |
− | ## '''Update:''' Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29367/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25809968 PubMed] | + | ## '''Update:''' Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29367/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436272/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25809968 PubMed] |
==Cytarabine (Cytosar) {{#subobject:25e1c6|Regimen=1}}== | ==Cytarabine (Cytosar) {{#subobject:25e1c6|Regimen=1}}== | ||
Line 902: | Line 902: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533673/ Sekeres et al. 2012] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|LDAC & Lintuzumab | |LDAC & Lintuzumab | ||
Line 912: | Line 912: | ||
|style="background-color:#eeee00"|Seems not superior | |style="background-color:#eeee00"|Seems not superior | ||
|- | |- | ||
− | |rowspan=2|[ | + | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536889/ Dennis et al. 2015] |
|rowspan=2 style="background-color:#00cd00"|Randomized | |rowspan=2 style="background-color:#00cd00"|Randomized | ||
|LDAC & [[Vosaroxin_(SNS_595)|Vosaroxin]] | |LDAC & [[Vosaroxin_(SNS_595)|Vosaroxin]] | ||
Line 925: | Line 925: | ||
|style="background-color:#ff0000"|Might have inferior CR rate | |style="background-color:#ff0000"|Might have inferior CR rate | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ Dombret et al. 2015] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Azacitidine_.28Vidaza.29|Azacitidine]] | |[[Acute_myeloid_leukemia#Azacitidine_.28Vidaza.29|Azacitidine]] | ||
Line 943: | Line 943: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ Kantarjian et al. 2012] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Decitabine_.28Dacogen.29|Decitabine]] | |[[Acute_myeloid_leukemia#Decitabine_.28Dacogen.29|Decitabine]] | ||
Line 956: | Line 956: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | <!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | ||
− | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] | + | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] |
− | # Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan;98(1):119-28. Epub 2012 Jul 16. [http://www.haematologica.org/content/98/1/119.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533673/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22801961 PubMed] | + | # Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan;98(1):119-28. Epub 2012 Jul 16. [http://www.haematologica.org/content/98/1/119.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533673/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22801961 PubMed] |
# Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK; UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013 Aug 22;122(8):1384-94. Epub 2013 Jul 9. [http://www.bloodjournal.org/content/122/8/1384.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23838349 PubMed] | # Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK; UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013 Aug 22;122(8):1384-94. Epub 2013 Jul 9. [http://www.bloodjournal.org/content/122/8/1384.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23838349 PubMed] | ||
− | # Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015 May 7;125(19):2923-32. Epub 2015 Mar 24. [http://www.bloodjournal.org/content/125/19/2923.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25805811 PubMed] | + | # Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015 May 7;125(19):2923-32. Epub 2015 Mar 24. [http://www.bloodjournal.org/content/125/19/2923.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536889/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25805811 PubMed] |
# Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015 Jun;29(6):1312-9. Epub 2015 Feb 13. [http://www.nature.com/leu/journal/v29/n6/full/leu201538a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25676423 PubMed] | # Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015 Jun;29(6):1312-9. Epub 2015 Feb 13. [http://www.nature.com/leu/journal/v29/n6/full/leu201538a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25676423 PubMed] | ||
− | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] | + | # Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. [http://www.bloodjournal.org/content/126/3/291.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504945/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25987659 PubMed] |
==Cytarabine, Daunorubicin, Sorafenib {{#subobject:6ad412|Regimen=1}}== | ==Cytarabine, Daunorubicin, Sorafenib {{#subobject:6ad412|Regimen=1}}== | ||
Line 1,003: | Line 1,003: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320000/ Issa et al. 2014] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[Acute_myeloid_leukemia#Decitabine_.26_Valproate|Decitabine & Valproate]] | |[[Acute_myeloid_leukemia#Decitabine_.26_Valproate|Decitabine & Valproate]] | ||
Line 1,021: | Line 1,021: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ Kantarjian et al. 2012] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29|Cytarabine]]<br> [[Acute_myeloid_leukemia#Best_supportive_care|Best supportive care]] | |[[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29|Cytarabine]]<br> [[Acute_myeloid_leukemia#Best_supportive_care|Best supportive care]] | ||
Line 1,040: | Line 1,040: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867720/ Blum et al. 2010] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,048: | Line 1,048: | ||
====Supportive medications==== | ====Supportive medications==== | ||
− | *[[Hydroxyurea (Hydrea)]] allowed during and prior to cycle 1 in order to maintain WBC less than 40 | + | *[[Hydroxyurea (Hydrea)]] allowed during and prior to cycle 1 in order to maintain WBC count less than 40 x 10<sup>9</sup>/L |
'''28-day cycles''' | '''28-day cycles''' | ||
Line 1,057: | Line 1,057: | ||
===References=== | ===References=== | ||
− | # Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. [http://www.pnas.org/content/107/16/7473.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20368434 PubMed] | + | # Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. [http://www.pnas.org/content/107/16/7473.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867720/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20368434 PubMed] |
<!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | <!-- Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. --> | ||
− | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] | + | # Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. [http://jco.ascopubs.org/content/30/21/2670.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874148/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22689805 PubMed] |
− | # Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29085/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25336333 PubMed] | + | # Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29085/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320000/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25336333 PubMed] |
==Decitabine & Valproate {{#subobject:948b49|Regimen=1}}== | ==Decitabine & Valproate {{#subobject:948b49|Regimen=1}}== | ||
Line 1,075: | Line 1,075: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895437/ Garcia-Manero et al. 2006] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|style="background-color:#d3d3d3"| | |style="background-color:#d3d3d3"| | ||
|style="background-color:#d3d3d3"| | |style="background-color:#d3d3d3"| | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320000/ Issa et al. 2014] |
|style="background-color:#00cd00"|Randomized Phase II | |style="background-color:#00cd00"|Randomized Phase II | ||
|[[Acute_myeloid_leukemia#Decitabine_.26_Valproate|Decitabine & Valproate]] | |[[Acute_myeloid_leukemia#Decitabine_.26_Valproate|Decitabine & Valproate]] | ||
Line 1,093: | Line 1,093: | ||
===References=== | ===References=== | ||
− | # Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15;108(10):3271-9. Epub 2006 Aug 1. [http://www.bloodjournal.org/content/108/10/3271.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16882711 PubMed] | + | # Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15;108(10):3271-9. Epub 2006 Aug 1. [http://www.bloodjournal.org/content/108/10/3271.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895437/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16882711 PubMed] |
− | # Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29085/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25336333 PubMed] | + | # Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29085/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320000/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25336333 PubMed] |
==ICL {{#subobject:a904d7|Regimen=1}}== | ==ICL {{#subobject:a904d7|Regimen=1}}== | ||
Line 1,199: | Line 1,199: | ||
===References=== | ===References=== | ||
− | # Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. Epub 2013 Sep 9. [http://onlinelibrary.wiley.com/doi/10.1002/ajh.23544/references long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23877926 PubMed] | + | # Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. Epub 2013 Sep 9. [http://onlinelibrary.wiley.com/doi/10.1002/ajh.23544/references long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110914/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23877926 PubMed] |
==Clofarabine & low-dose Cytarabine alternating with Decitabine {{#subobject:756e06|Regimen=1}}== | ==Clofarabine & low-dose Cytarabine alternating with Decitabine {{#subobject:756e06|Regimen=1}}== | ||
Line 1,211: | Line 1,211: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907176/ Faderl et al. 2010] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,230: | Line 1,230: | ||
===References=== | ===References=== | ||
− | # Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27429/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22282348 PubMed] | + | # Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.27429/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907176/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22282348 PubMed] |
− | ## '''Update:''' Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29367/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25809968 PubMed] | + | ## '''Update:''' Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.29367/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436272/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25809968 PubMed] |
==Cytarabine & Daunorubicin {{#subobject:d6f810|Regimen=1}}== | ==Cytarabine & Daunorubicin {{#subobject:d6f810|Regimen=1}}== | ||
Line 1,305: | Line 1,305: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ Ravandi et al. 2010] |
|style="background-color:#eeee00"|Phase I/II | |style="background-color:#eeee00"|Phase I/II | ||
|- | |- | ||
Line 1,322: | Line 1,322: | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
− | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] | + | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] |
− | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] | + | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091714/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] |
==Cytarabine, Idarubicin, Vorinostat {{#subobject:5fc722|Regimen=1}}== | ==Cytarabine, Idarubicin, Vorinostat {{#subobject:5fc722|Regimen=1}}== | ||
Line 1,335: | Line 1,335: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ Garcia-Manero et al. 2012] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,353: | Line 1,353: | ||
===References=== | ===References=== | ||
− | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] | + | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] |
==Etoposide & Mitoxantrone {{#subobject:ab1766|Regimen=1}}== | ==Etoposide & Mitoxantrone {{#subobject:ab1766|Regimen=1}}== | ||
Line 1,510: | Line 1,510: | ||
===References=== | ===References=== | ||
# Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903. [http://www.nejm.org/doi/full/10.1056/NEJM199410063311402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8078551 PubMed] | # Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903. [http://www.nejm.org/doi/full/10.1056/NEJM199410063311402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8078551 PubMed] | ||
− | # Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 1;105(9):3420-7. Epub 2004 Nov 30. [http://www.bloodjournal.org/content/105/9/3420.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15572587 PubMed] | + | # Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 1;105(9):3420-7. Epub 2004 Nov 30. [http://www.bloodjournal.org/content/105/9/3420.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895015/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/15572587 PubMed] |
# Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011 Feb 24;117(8):2366-72. Epub 2010 Dec 29. [http://www.bloodjournal.org/content/117/8/2366.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21190996 PubMed] | # Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011 Feb 24;117(8):2366-72. Epub 2010 Dec 29. [http://www.bloodjournal.org/content/117/8/2366.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21190996 PubMed] | ||
# Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011 Aug 18;118(7):1754-62. Epub 2011 Jun 20. [http://www.bloodjournal.org/content/118/7/1754.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21690555 PubMed] | # Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011 Aug 18;118(7):1754-62. Epub 2011 Jun 20. [http://www.bloodjournal.org/content/118/7/1754.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21690555 PubMed] | ||
Line 1,606: | Line 1,606: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829116/ Nand et al. 2013] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,636: | Line 1,636: | ||
# Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08235.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20497178 PubMed] | # Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08235.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20497178 PubMed] | ||
<!-- Presented in part at the American Society of Clinical Oncology annual meeting (Chicago, IL, June 1-5, 2012) and at the American Society of Hematology annual meeting (Atlanta, GA, December 8-11, 2012). --> | <!-- Presented in part at the American Society of Clinical Oncology annual meeting (Chicago, IL, June 1-5, 2012) and at the American Society of Hematology annual meeting (Atlanta, GA, December 8-11, 2012). --> | ||
− | # Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013 Nov 14;122(20):3432-9. Epub 2013 Oct 3. [http://www.bloodjournal.org/content/122/20/3432.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24092933 PubMed] | + | # Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013 Nov 14;122(20):3432-9. Epub 2013 Oct 3. [http://www.bloodjournal.org/content/122/20/3432.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829116/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24092933 PubMed] |
==Decitabine (Dacogen) {{#subobject:d8250a|Regimen=1}}== | ==Decitabine (Dacogen) {{#subobject:d8250a|Regimen=1}}== | ||
Line 1,649: | Line 1,649: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867720/ Blum et al. 2010] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,658: | Line 1,658: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Decitabine (Dacogen)]] 20 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 5 | *[[Decitabine (Dacogen)]] 20 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 5 | ||
− | **Patients with no evidence of residual disease by flow cytometry or cytogenetics who had grade 4 neutropenia (ANC less than 500/ | + | **Patients with no evidence of residual disease by flow cytometry or cytogenetics who had grade 4 neutropenia (ANC less than 500/uL) persisting greater than or equal to 14 days received 4 days instead of 5 days of decitabine starting with the following cycle. If neutropenia occurred again as above with 4 days of decitabine, patients received 3 days instead of 4 days of decitabine starting with the following cycle. |
'''28-day cycles, given until relapsed disease or unacceptable toxicity''' | '''28-day cycles, given until relapsed disease or unacceptable toxicity''' | ||
===References=== | ===References=== | ||
− | # Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. [http://www.pnas.org/content/107/16/7473.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20368434 PubMed] | + | # Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. [http://www.pnas.org/content/107/16/7473.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867720/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20368434 PubMed] |
==LoDAC/LDAC {{#subobject:4c65c8|Regimen=1}}== | ==LoDAC/LDAC {{#subobject:4c65c8|Regimen=1}}== | ||
Line 1,735: | Line 1,735: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591761/ Ocio et al. 2015 (panobidara)] |
|style="background-color:#eeee00"|Phase Ib/II | |style="background-color:#eeee00"|Phase Ib/II | ||
|- | |- | ||
Line 1,749: | Line 1,749: | ||
===References=== | ===References=== | ||
− | # Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. [http://www.haematologica.org/content/100/10/1294 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26160880 PubMed] | + | # Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. [http://www.haematologica.org/content/100/10/1294 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591761/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26160880 PubMed] |
==Sorafenib (Nexavar) {{#subobject:23822e|Regimen=1}}== | ==Sorafenib (Nexavar) {{#subobject:23822e|Regimen=1}}== | ||
Line 1,762: | Line 1,762: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ Ravandi et al. 2010] |
|style="background-color:#eeee00"|Phase I/II | |style="background-color:#eeee00"|Phase I/II | ||
|- | |- | ||
Line 1,780: | Line 1,780: | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
− | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] | + | # Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. [http://jco.ascopubs.org/content/28/11/1856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930809/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20212254 PubMed] |
− | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] | + | ## '''Update:''' Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. [http://www.nature.com/leu/journal/v28/n7/full/leu201454a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091714/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24487412 PubMed] |
# Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. Accessed January 26, 2017. [http://www.bloodadvances.org/content/1/5/331 link to original article] '''contains verified protocol''' | # Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. Accessed January 26, 2017. [http://www.bloodadvances.org/content/1/5/331 link to original article] '''contains verified protocol''' | ||
Line 1,795: | Line 1,795: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ Garcia-Manero et al. 2012] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,807: | Line 1,807: | ||
===References=== | ===References=== | ||
− | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] | + | # Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/18/2204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879705/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585696 PubMed] |
=Relapsed/refractory= | =Relapsed/refractory= | ||
Line 1,821: | Line 1,821: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ Zeidner et al. 2015] |
|style="background-color:#eeee00"|Non-randomized | |style="background-color:#eeee00"|Non-randomized | ||
|- | |- | ||
Line 1,834: | Line 1,834: | ||
===References=== | ===References=== | ||
− | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] | + | # Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26022709 PubMed] |
==ADE {{#subobject:d16134|Regimen=1}}== | ==ADE {{#subobject:d16134|Regimen=1}}== | ||
Line 1,904: | Line 1,904: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674666/ Ravandi et al. 2013] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 1,921: | Line 1,921: | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
− | # Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 6;121(23):4655-62. Epub 2013 Apr 23. [http://www.bloodjournal.org/content/121/23/4655.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23613521 PubMed] | + | # Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 6;121(23):4655-62. Epub 2013 Apr 23. [http://www.bloodjournal.org/content/121/23/4655.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674666/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23613521 PubMed] |
==Cladribine (Leustatin) {{#subobject:b80308|Regimen=1}}== | ==Cladribine (Leustatin) {{#subobject:b80308|Regimen=1}}== | ||
Line 1,962: | Line 1,962: | ||
*[[Cladribine (Leustatin)]] 5 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 5, '''given first''' | *[[Cladribine (Leustatin)]] 5 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 5, '''given first''' | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 2 hours after [[Cladribine (Leustatin)]]''' | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 2 hours after [[Cladribine (Leustatin)]]''' | ||
− | *[[Filgrastim (Neupogen)]] 300 | + | *[[Filgrastim (Neupogen)]] 300 mcg SC once per day on days -1 to 5; first dose is given 24 hours before first dose of [[Cladribine (Leustatin)]] |
===References=== | ===References=== | ||
Line 1,990: | Line 1,990: | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 2 hours after cladribine''' | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 2 hours after cladribine''' | ||
*[[Filgrastim (Neupogen)]] based on WBC count: | *[[Filgrastim (Neupogen)]] based on WBC count: | ||
− | **WBC less than or equal to | + | **WBC count less than or equal to 20 x 10<sup>9</sup>/L: 300 mcg SC once per day on days 0 to 5; '''first dose is given 24 hours prior to chemotherapy''' |
− | **WBC greater than | + | **WBC count greater than 20 x 10<sup>9</sup>/L: 300 mcg SC once per day on days 1 to 5, '''commenced simultaneously to cladribine''' |
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 to 3 | *[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
Line 2,035: | Line 2,035: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874149/ Faderl et al. 2012 (CLASSIC I)] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29_2|Cytarabine]] | |[[Acute_myeloid_leukemia#Cytarabine_.28Cytosar.29_2|Cytarabine]] | ||
Line 2,094: | Line 2,094: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228084/ Agura et al. 2011] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 2,119: | Line 2,119: | ||
===References=== | ===References=== | ||
# Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1;105(3):940-7. Epub 2004 Oct 14. [http://www.bloodjournal.org/content/105/3/940.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15486072 PubMed] | # Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1;105(3):940-7. Epub 2004 Oct 14. [http://www.bloodjournal.org/content/105/3/940.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15486072 PubMed] | ||
− | # Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C, Li S, Saracino G, Tadic-Ovcina M, Fay J. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist. 2011;16(2):197-206. Epub 2011 Jan 27. [http://theoncologist.alphamedpress.org/content/16/2/197.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21273514 PubMed] | + | # Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C, Li S, Saracino G, Tadic-Ovcina M, Fay J. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist. 2011;16(2):197-206. Epub 2011 Jan 27. [http://theoncologist.alphamedpress.org/content/16/2/197.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228084/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21273514 PubMed] |
<!-- Presented in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and at the 16th Congress of the European Hematology Association, London, United Kingdom, June 9-12, 2011. --> | <!-- Presented in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and at the 16th Congress of the European Hematology Association, London, United Kingdom, June 9-12, 2011. --> | ||
− | # Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/20/2492.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585697 PubMed] | + | # Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/20/2492.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874149/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585697 PubMed] |
# Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. Br J Haematol. 2015 Aug;170(3):349-55. Epub 2015 Apr 8. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13437/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2584284 PubMed] | # Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. Br J Haematol. 2015 Aug;170(3):349-55. Epub 2015 Apr 8. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13437/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2584284 PubMed] | ||
# Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. Epub 2015 Aug 18. [http://www.nature.com/leu/journal/v30/n2/full/leu2015226a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26283567 PubMed] | # Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. Epub 2015 Aug 18. [http://www.nature.com/leu/journal/v30/n2/full/leu2015226a.html link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26283567 PubMed] | ||
Line 2,137: | Line 2,137: | ||
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874149/ Faderl, et al. 2012 (CLASSIC I)] |
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[#Clofarabine_.26_Cytarabine|Clofarabine & Cytarabine]] | |[[#Clofarabine_.26_Cytarabine|Clofarabine & Cytarabine]] | ||
Line 2,159: | Line 2,159: | ||
===References=== | ===References=== | ||
<!-- Presented in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and at the 16th Congress of the European Hematology Association, London, United Kingdom, June 9-12, 2011. --> | <!-- Presented in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, and at the 16th Congress of the European Hematology Association, London, United Kingdom, June 9-12, 2011. --> | ||
− | # Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/20/2492.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585697 PubMed] | + | # Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. [http://jco.ascopubs.org/content/30/20/2492.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874149/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585697 PubMed] |
− | # Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep;16(9):1025-36. Epub 2015 Jul 30.[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00201-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26234174 PubMed] | + | # Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep;16(9):1025-36. Epub 2015 Jul 30.[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00201-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822512/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26234174 PubMed] |
==Cytarabine & Mitoxantrone {{#subobject:fba448|Regimen=1}}== | ==Cytarabine & Mitoxantrone {{#subobject:fba448|Regimen=1}}== | ||
Line 2,223: | Line 2,223: | ||
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, '''given first''' | *[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, '''given first''' | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 4 hours after the start of [[Fludarabine (Fludara)]]''' | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, '''given second, 4 hours after the start of [[Fludarabine (Fludara)]]''' | ||
− | *[[Filgrastim (Neupogen)]] or [[Lenograstim (Granocyte)]] 5 | + | *[[Filgrastim (Neupogen)]] or [[Lenograstim (Granocyte)]] 5 mcg/kg SC once per day starting on day -1 (the paper described this as "day 0"), first dose given 24 hours before first dose of chemotherapy, to continue until neutrophil recovery |
===References=== | ===References=== | ||
Line 2,246: | Line 2,246: | ||
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, given first | *[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5, given first | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, given second, 4 hours after [[Fludarabine (Fludara)]] | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, given second, 4 hours after [[Fludarabine (Fludara)]] | ||
− | *[[Filgrastim (Neupogen)]] 5 | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day 6, to continue until neutrophil recovery |
*[[Idarubicin (Idamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 to 3 | *[[Idarubicin (Idamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
Line 2,278: | Line 2,278: | ||
*[[Fludarabine (Fludara)]] 15 mg/m<sup>2</sup> IV 4 hours prior to [[Cytarabine (Cytosar)]] | *[[Fludarabine (Fludara)]] 15 mg/m<sup>2</sup> IV 4 hours prior to [[Cytarabine (Cytosar)]] | ||
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV BID on days 1, 2, 8, 9 | *[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV BID on days 1, 2, 8, 9 | ||
− | ** | + | **Dose increased to 3000 mg/m<sup>2</sup> for patients 60 or younger with refractory AML or greater than or equal to 2nd relapse |
*[[Idarubicin (Idamycin)]] 10? mg/m<sup>2</sup> IV once per day on days 3, 4, 10, 11 | *[[Idarubicin (Idamycin)]] 10? mg/m<sup>2</sup> IV once per day on days 3, 4, 10, 11 | ||
Line 2,298: | Line 2,298: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834701/ Becker et al. 2011] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Filgrastim (Neupogen)]] 5 | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting day -1, continuing until ANC at least 2000/uL for 2 consecutive days |
*[[Clofarabine (Clolar)]] 25 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 5, given first | *[[Clofarabine (Clolar)]] 25 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 5, given first | ||
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, given second, 4 hours after start of [[Clofarabine (Clolar)]] infusion | *[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 to 5, given second, 4 hours after start of [[Clofarabine (Clolar)]] infusion | ||
Line 2,311: | Line 2,311: | ||
===References=== | ===References=== | ||
− | # Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011 Oct;155(2):182-9. Epub 2011 Aug 18. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08831.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21848522 PubMed] | + | # Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011 Oct;155(2):182-9. Epub 2011 Aug 18. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08831.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834701/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21848522 PubMed] |
==IAP {{#subobject:7a1294|Regimen=1}}== | ==IAP {{#subobject:7a1294|Regimen=1}}== | ||
Line 2,325: | Line 2,325: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188732/ Advani et al. 2014 (SWOG S0919)] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 2,338: | Line 2,338: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Anjali S. Advani, Shannon McDonough, Edward Copelan, Cheryl L. Willman, Deborah A. Mulford, Alan F. List, Mikkael A. Sekeres, Megan Othus, Harry P. Erba, Frederick R. Appelbaum. SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). J Clin Oncol 31, 2013 (suppl; abstr 7028). [http://meetinglibrary.asco.org/content/111137-132 link to abstract] '''contains verified protocol''' --> | <!-- # '''Abstract:''' Anjali S. Advani, Shannon McDonough, Edward Copelan, Cheryl L. Willman, Deborah A. Mulford, Alan F. List, Mikkael A. Sekeres, Megan Othus, Harry P. Erba, Frederick R. Appelbaum. SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). J Clin Oncol 31, 2013 (suppl; abstr 7028). [http://meetinglibrary.asco.org/content/111137-132 link to abstract] '''contains verified protocol''' --> | ||
− | # Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol. 2014 Oct;167(2):233-7. Epub 2014 Jul 18. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13035/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25039477 PubMed] | + | # Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol. 2014 Oct;167(2):233-7. Epub 2014 Jul 18. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13035/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188732/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25039477 PubMed] |
==MEC {{#subobject:48e49b|Regimen=1}}== | ==MEC {{#subobject:48e49b|Regimen=1}}== | ||
Line 2,409: | Line 2,409: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081383/ Eghtedar et al. 2012] |
|style="background-color:#eeee00"|Phase II | |style="background-color:#eeee00"|Phase II | ||
|- | |- | ||
Line 2,422: | Line 2,422: | ||
===References=== | ===References=== | ||
<!-- This study was presented in part at the American Society of Hematology annual meeting, December 2010, Orlando, FL. --> | <!-- This study was presented in part at the American Society of Hematology annual meeting, December 2010, Orlando, FL. --> | ||
− | # Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614-8. Epub 2012 Mar 15. [http://www.bloodjournal.org/content/119/20/4614.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22422826 PubMed] | + | # Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614-8. Epub 2012 Mar 15. [http://www.bloodjournal.org/content/119/20/4614.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081383/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22422826 PubMed] |
==SHAI {{#subobject:6f1931|Regimen=1}}== | ==SHAI {{#subobject:6f1931|Regimen=1}}== | ||
Line 2,446: | Line 2,446: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV BID on days 1, 2, 8, 9 | *[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV BID on days 1, 2, 8, 9 | ||
− | ** | + | **Dose increased to 3000 mg/m<sup>2</sup> for patients 60 or younger with refractory AML or greater than or equal to 2nd relapse |
*[[Idarubicin (Idamycin)]] 10?mg/m<sup>2</sup> IV once per day on days 3, 4, 10, 11 | *[[Idarubicin (Idamycin)]] 10?mg/m<sup>2</sup> IV once per day on days 3, 4, 10, 11 | ||
Line 2,508: | Line 2,508: | ||
==Antifungal prophylaxis== | ==Antifungal prophylaxis== | ||
− | # Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood. 2015 Dec 24;126(26):2790-7. Epub 2015 Oct 26. Review. [http://www.bloodjournal.org/content/126/26/2790.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26504183 PubMed] | + | # Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood. 2015 Dec 24;126(26):2790-7. Epub 2015 Oct 26. Review. [http://www.bloodjournal.org/content/126/26/2790.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692139/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26504183 PubMed] |
[[Category:Acute myeloid leukemia regimens]] | [[Category:Acute myeloid leukemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Disease index]] | [[Category:Disease index]] |
Revision as of 14:35, 29 July 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
88 regimens on this page
150 variants on this page
|
Guidelines
ELN
Current
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2017) link to PMC article PubMed
Older
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet (2010) PubMed
ESMO
- Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) PubMed
NCCN
Induction therapy, standard patients
ADE
back to top |
ADE: Ara-C (Cytarabine), Daunorubicin, Etoposide
Regimen #1, high-dose Ara-C
Study | Evidence | Comparator | Efficacy |
Willemze et al. 2013 (AML-12) | Phase III | Cytarabine (standard-dose), Daunorubicin, Etoposide | Might have superior OS |
Chemotherapy
- Cytarabine (Cytosar) 3000 mg/m2 IV over 3 hours q12h on days 1, 3, 5, 7
- Daunorubicin (Cerubidine) 50 mg/m2 IV over 5 minutes once per day on days 1, 3, 5
- Etoposide (Vepesid) 50 mg/m2 IV over 1 hour once per day on days 1 to 5
7-day course
Regimen #2, standard-dose Ara-C
Study | Evidence | Comparator | Efficacy |
Willemze et al. 2013 (AML-12) | Phase III | Cytarabine (high-dose), Daunorubicin, Etoposide | Might have inferior OS |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 10 (total dose: 1000 mg/m2)
- Daunorubicin (Cerubidine) 50 mg/m2 IV over 5 minutes once per day on days 1, 3, 5
- Etoposide (Vepesid) 50 mg/m2 IV over 1 hour once per day on days 1 to 5
10-day course
References
- Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996 Mar 1;87(5):1710-7. link to original article PubMed
- Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Epub 2013 Aug 12. link to original article PubMed
- Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. J Clin Oncol. 2014 Jan 20;32(3):219-28. Epub 2013 Dec 2. link to original article contains verified protocol PubMed
CIA
back to top |
CIA: Clofarabine, Idarubicin, Ara-C (Cytarabine)
Regimen
Study | Evidence |
Nazha et al. 2013 | Phase II |
Chemotherapy
- Clofarabine (Clolar) 20 mg/m2 IV over 1 hour once per day on days 1 to 5
- Idarubicin (Idamycin) 10 mg/m2 IV over 30 minutes once per day on days 1 to 3
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 1 to 5
Supportive medications
- Prophylactic Levofloxacin (Levaquin), Itraconazole (Sporanox), and Valacyclovir (Valtrex) were administered to all patients
- Granulocyte colony-stimulating factor neither mandated nor forbidden and given per physician discretion
5-day course
Patients with only partial remission underwent a second course with the same drugs, doses, and schedule. Patients who achieved a CR or CRi (complete remission with incomplete platelet recovery) proceeded to Clofarabine, Idarubicin, and Cytarabine (CIA) Consolidation.
References
- Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. Epub 2013 Sep 9. link to PubMed Central article contains verified protocol PubMed
Cytarabine & Daunorubicin
back to top |
7+3d: 7 days of cytarabine + 3 days of daunorubicin
Regimen #1, 7+3d with standard-dose dauno (45 mg/m2), CI Ara-C (100 mg/m2)
Study | Evidence | Comparator | Efficacy |
Rai et al. 1981 (CALGB) | Phase III | 7+3d (bolus Ara-C) | Seems to have superior CR rate |
5+2d | Superior CR rate | ||
5+2d (bolus Ara-C) | Superior CR rate | ||
Yates et al. 1982 (CALGB) | Phase III | 7+3d, low-dose dauno (30 mg/m2) | Seems not superior |
7+3a (30 mg/m2) | Seems not superior | ||
Preisler et al. 1987 (CALGB) | Phase III | 10+3d | Seems not superior |
TAD | Seems not superior | ||
Wiernik et al. 1992 | Phase III | 7+3i | Seems to have inferior OS |
Rowe et al. 2004 | Phase III | 7+3d + GM-CSF 7+3i 7+3i + GM-CSF 7+3m 7+3m + GM-CSF |
Seems not superior |
Fernandez et al. 2009 (ECOG E1900) | Phase III | 7+3d (high-dose) | Inferior OS |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Daunorubicin (Cerubidine) 45 mg/m2 IV once per day on days 1 to 3
7-day course
Patients in Rowe et al. 2004 with persistent disease at day 14 (greater than 5% blasts) underwent an identical second cycle of 7+3i. In Stone et al. 2015, patients received a second course of the same regimen if their day 14 bone marrow was positive. Patients with PR or better at time of count recovery received allogeneic stem cell transplant if eligible, otherwise HiDAC if younger than 60 or MiDAC if greater than or equal to 60.
Regimen #2, 7+3d with standard-dose dauno (45 mg/m2), CI Ara-C (200 mg/m2)
Study | Evidence | Comparator | Efficacy |
Löwenberg et al. 2009 (HOVON/AMLSG/SAKK) | Phase III | 7+3d, high-dose dauno | Inferior CR rate |
Stone et al. 2015 (ACCEDE) | Phase III | Amonafide & Cytarabine | Seems not superior |
Chemotherapy
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m2)
- Daunorubicin (Cerubidine) 45 mg/m2 IV once per day on days 1 to 3
7-day course
Treatment followed by MiDAC consolidation.
Regimen #3, 7+3d with intermediate-dose dauno (60 mg/m2), CI Ara-C (200 mg/m2)
Study | Evidence | Comparator | Efficacy |
Holowiecki et al. 2004 (PALG AML1/1999) | Phase III | DAC | Inferior CR rate after first induction |
Holowiecki et al. 2012 (PALG AML1/2004) | Phase III | DAC | Seems to have inferior OS |
DAF | Seems not superior |
Chemotherapy
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m2)
- Daunorubicin (Cerubidine) 60 mg/m2 IV over 5 minutes once per day on days 1 to 3
Supportive medications
- "according to commonly accepted guidelines with no prophylactic IV antibiotics"
- Granulocyte colony-stimulating factor recommended only for patients greater than 50 years old whose leukemic blasts were negative for CD114 expression
7-day course
Patients with only partial remission in both studies underwent a second course with the same drugs, doses, and schedule. Non-responders in PALG AML1/1999 proceeded to salvage therapy with CLAG. Patients in remission underwent consolidation with HAM followed by HiDAC.
Regimen #4, 7+3d with standard-dose dauno (40 mg/m2), intermittent Ara-C
Study | Evidence | Comparator | Efficacy |
Masaoka et al. 1996 | Randomized Phase II | 7+3i | Seems to have inferior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 80 mg/m2 IV over 2 hours q12h on days 1 to 7
- Daunorubicin (Cerubidine) 40 mg/m2 IV bolus once per day on days 1 to 3
7-day course
Regimen #5, 7+3d with high-dose dauno (90 mg/m2), CI Ara-C (100 mg/m2)
Study | Evidence | Comparator | Efficacy |
Fernandez et al. 2009 (ECOG E1900) | Phase III | 7+3d, standard-dose dauno | Superior OS |
Zeidner et al. 2015 | Randomized Phase II | FLAM | Inferior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Daunorubicin (Cerubidine) 90 mg/m2 IV once per day on days 1 to 3
7-day course
Patients with residual leukemia at day 14 in Zeidner et al. 2015 underwent 5+2d.
Regimen #6, 7+3d with high-dose dauno (90 mg/m2), CI Ara-C (200 mg/m2)
Study | Evidence | Comparator | Efficacy |
Löwenberg et al. 2009 (HOVON/AMLSG/SAKK) | Phase III | 7+3d, standard-dose dauno | Superior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m2)
- Daunorubicin (Cerubidine) 90 mg/m2 IV once per day on days 1 to 3
7-day course
Treatment followed by MiDAC consolidation.
Regimen #7, 5+3d with standard-dose dauno (50 mg/m2)
Study | Evidence | Comparator | Efficacy |
Berman et al. 1991 (L-19 Protocol) | Phase III | 5+3i | Inferior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 25 mg/m2 IV bolus, followed by 200 mg/m2/day IV continuous infusion on days 1 to 5
- Daunorubicin (Cerubidine) 50 mg/m2 IV once per day on days 1 to 3
5-day course
References
- Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981 Dec;58(6):1203-12. link to original article contains verified protocol PubMed
- Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982 Aug;60(2):454-62. link to original article contains verified protocol PubMed
- Preisler H, Davis RB, Kirshner J, Dupre E, Richards F 3rd, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987 May;69(5):1441-9. link to original article contains verified protocol PubMed
- Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991 Apr 15;77(8):1666-74. link to original article contains verified protocol PubMed
- Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9. link to original article contains verified protocol PubMed
- Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7. contains protocol PubMed
- Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996 Oct 15;88(8):2841-51. link to original article PubMed
- Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004 Jan 15;103(2):479-85. Epub 2003 Sep 25. link to original article contains verified protocol PubMed
- Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. link to original article contains verified protocol PubMed
- Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1235-48. Erratum in: N Engl J Med. 2010 Mar 25;362(12):1155. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text. link to original article contains verified protocol PubMed
- Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59. link to original article contains verified protocol link to PMC article PubMed
- Update: Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8. Epub 2016 Jan 11. link to original article link to PMC article PubMed
- Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. link to original article contains verified protocol PubMed
- Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16. Epub 2012 Apr 5. link to original article PubMed
- Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012 Nov 10;30(32):3924-31. Epub 2012 Jul 30. link to original article PubMed
- Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013 Sep 1;31(25):3110-8. Epub 2013 Jul 29. link to original article PubMed
- Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Epub 2013 Aug 12. link to original article PubMed
- Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878-85. Epub 2015 Apr 1. link to original article link to PMC article PubMed
- Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10;33(11):1252-7. Epub 2015 Mar 2. link to original article contains verified protocol PubMed
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. link to original article contains protocol link to PMC article PubMed
- Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed
- Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015 Dec;16(16):1691-9. Epub 2015 Nov 6. link to original article PubMed
- Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017
Feb;31(2):310-317. Epub 2016 Sep 2. link to original article link to PMC article PubMed
Cytarabine, Daunorubicin, Midostaurin
Cytarabine, Daunorubicin, and Midostaurin induction therapy for acute myeloid leukemia (AML)
Cytarabine & Idarubicin
back to top |
7+3i: 7 days of cytarabine + 3 days of idarubicin
Regimen #1, 7+3i with standard-dose ida (12 mg/m2), CI Ara-C (200 mg/m2)
Study | Evidence | Comparator | Efficacy |
Pautas et al. 2010 (ALFA-9801) | Phase III | 7+3d (high-dose) 7+4i |
Seems not superior |
Löwenberg et al. 2017 (HOVON-102) | Phase III | 7+3i & Clofarabine | Seems not superior |
Chemotherapy
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m2)
- Idarubicin (Idamycin) 12 mg/m2 IV over 3 hours once per day on days 1 to 3
7-day course
Patients achieiving CR in ALFA-9801 proceeded to cytarabine & idarubicin consolidation.
Regimen #2, 7+3i with standard-dose ida (12 mg/m2), CI Ara-C (100 mg/m2)
Study | Evidence | Comparator | Efficacy |
Haas et al. 1993 | Non-randomized | ||
Rowe et al. 2004 | Phase III | 7+3d 7+3d + GM-CSF 7+3i + GM-CSF 7+3m 7+3m + GM-CSF |
Seems not superior |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Idarubicin (Idamycin) 12 mg/m2 IV once per day on days 1 to 3
7-day course
Patients in Rowe et al. 2004 with persistent disease at day 14 (greater than 5% blasts) underwent an identical second cycle of 7+3i.
Regimen #3, 7+3i with higher-dose ida (13 mg/m2), CI Ara-C (100 mg/m2)
Study | Evidence | Comparator | Efficacy |
Wiernik et al. 1992 | Phase III | 7+3d | Seems to have superior OS |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Idarubicin (Idamycin) 13 mg/m2 IV once per day on days 1 to 3
7-day course
Regimen #4, 7+3i with standard-dose ida (12 mg/m2), intermittent Ara-C
Study | Evidence | Comparator | Efficacy |
Masaoka et al. 1996 | Randomized Phase II | 7+3d | Seems to have superior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 80 mg/m2 IV over 2 hours q12h on days 1 to 7
- Idarubicin (Idamycin) 12 mg/m2 IV bolus once per day on days 1 to 3
7-day course
Regimen #5, 5+3i
Study | Evidence | Comparator | Efficacy |
Berman et al. 1991 (L-19 Protocol) | Phase III | 5+3d | Superior CR rate |
Chemotherapy
- Cytarabine (Cytosar) 25 mg/m2 IV bolus, followed by 200 mg/m2/day IV continuous infusion on days 1 to 5
- Idarubicin (Idamycin) 12 mg/m2 IV bolus once per day on days 1 to 3
5-day course
References
- Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991 Apr 15;77(8):1666-74. link to original article contains verified protocol PubMed
- Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9. link to original article contains verified protocol PubMed
- Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Semin Oncol. 1993 Dec;20(6 Suppl 8):20-6. PubMed
- Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7. contains protocol PubMed
- Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004 Jan 15;103(2):479-85. Epub 2003 Sep 25. link to original article contains verified protocol PubMed
- Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010 Feb 10;28(5):808-14. Epub 2010 Jan 4. link to original article contains verified protocol PubMed
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. link to original article contains verified protocol link to PMC article PubMed
- Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017 Mar 23;129(12):1636-1645. Epub 2017 Jan 3. link to original article contains verified protocol PubMed
Cytarabine & Idarubicin -> Amsacrine & Cytarabine
back to top |
Note: Amsacrine is not generally available; this reference is here for historic purposes, only.
References
- Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M; Dutch-Belgian Hemato-Oncology Cooperative Group.; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003 Aug 21;349(8):743-52. link to original article PubMed
- Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011 Mar 17;364(11):1027-36. link to original article PubMed
Cytarabine, Idarubicin, Sorafenib
back to top |
Regimen
Study | Evidence |
Ravandi et al. 2010 | Phase I/II |
Regimen details are from the phase II part of the published phase I/II trial.
Chemotherapy
- Cytarabine (Cytosar) 1500 mg/m2/day IV continuous infusion on days 1 to 4 (total dose: 6000 mg/m2)
- Patients older than 60 received: 1500 mg/m2/day IV continuous infusion on days 1 to 3 (total dose: 4500 mg/m2)
- Idarubicin (Idamycin) 12 mg/m2 IV over 1 hour once per day on days 1 to 3
- Sorafenib (Nexavar) 400 mg PO BID on days 1 to 7
7-day course
Treatment followed by cytarabine, idarubicin, sorafenib consolidation.
References
- Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. link to original article contains verified protocol link to PMC article PubMed
- Update: Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. link to original article link to PMC article PubMed
Cytarabine, Idarubicin, Vorinostat
back to top |
Regimen
Study | Evidence |
Garcia-Manero et al. 2012 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 1500 mg/m2/day IV continuous infusion on days 4 to 7 (total dose: 6000 mg/m2)
- Patients older than 60 received: 1500 mg/m2/day IV continuous infusion on days 4 to 6 (total dose: 4500 mg/m2)
- Idarubicin (Idamycin) 12 mg/m2 IV once per day on days 4 to 6
- Vorinostat (Zolinza) 500 mg PO TID on days 1 to 3
Supportive medications
- Methylprednisolone (Solumedrol) (note: the paper spelled this as "salumedrol"--it's assumed this is what they meant) 50 mg IV on days of Cytarabine (Cytosar) to prevent fever and rash
7-day course for 1 to 2 cycles
To be followed by Cytarabine, Idarubicin, Vorinostat consolidation therapy.
References
- Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
Cytarabine & Mitoxantrone
back to top |
7+3m: 7 days of cytarabine + 3 days of mitoxantrone
Regimen
Study | Evidence | Comparator | Efficacy |
Rowe et al. 2004 | Phase III | 7+3d 7+3d + GM-CSF 7+3i 7+3i + GM-CSF 7+3m + GM-CSF |
Seems not superior |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Mitoxantrone (Novantrone) 12 mg/m2 IV once per day on days 1 to 3
7-day course
Patients with persistent disease at day 14 (greater than 5% blasts) underwent an identical second cycle of 7+3m.
References
- Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004 Jan 15;103(2):479-85. Epub 2003 Sep 25. link to original article contains verified protocol PubMed
DAC
back to top |
DAC: Daunorubicin, Ara-C (Cytarabine), Cladribine
Regimen
Study | Evidence | Comparator | Efficacy |
Holowiecki et al. 2004 (PALG AML1/1999) | Phase III | DA | Superior CR rate after first induction |
Holowiecki et al. 2012 (PALG AML1/2004) | Phase III | DA | Seems to have superior OS |
DAF | Seems not superior |
Chemotherapy
- Daunorubicin (Cerubidine) 60 mg/m2 IV over 5 minutes once per day on days 1 to 3
- Cytarabine (Cytosar) 200 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m2)
- Cladribine (Leustatin) 5 mg/m2 IV over 3 hours once per day on days 1 to 5
Supportive medications
- "according to commonly accepted guidelines with no prophylactic IV antibiotics"
- Granulocyte colony-stimulating factor recommended only for patients greater than 50 years old whose leukemic blasts were negative for CD114 expression
7-day course
Patients with only partial remission in both studies underwent a second course with the same drugs, doses, and schedule. Non-responders in PALG AML1/1999 proceeded to salvage therapy with CLAG. Patients in remission underwent consolidation with HAM followed by HiDAC.
References
- Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. link to original article contains verified protocol PubMed
- Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. link to original article contains verified protocol PubMed
FLAG-Ida
back to top |
FLAG-Ida: FLudarabine, Ara-C (Cytarabine), G-CSF (Lenograstim), Idarubicin
Regimen
Study | Evidence | Comparator | Efficacy |
Burnett et al. 2013 (MRC AML15) | Phase III | ADE | Seems not superior |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days 2 to 6
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 2 to 6, given 4 hours after Fludarabine (Fludara)
- Lenograstim (Granocyte) 263 mcg SC once per day on days 1 to 7
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 4 to 6
References
- Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Epub 2013 Aug 12. link to original article contains protocol PubMed
FLAM
back to top |
FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone
Regimen
Study | Evidence | Comparator | Efficacy |
Zeidner et al. 2015 | Randomized Phase II | 7+3d, high-dose dauno | Superior CR rate |
Chemotherapy
- Alvocidib (Flavopiridol) 50 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Cytosar) 667 mg/m2/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m2)
- Mitoxantrone (Novantrone) 40 mg/m2 IV once on day 9
One course
References
- Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed
MICE
back to top |
MICE: MItoxantrone, Cytarabine, Etoposide
Regimen
Study | Evidence | Comparator | Efficacy |
Amadori et al. 2013 (EORTC/GIMEMA AML-17) | Phase III | GO -> MICE | Might have superior OS |
Chemotherapy
- Mitoxantrone (Novantrone) 7 mg/m2 IV once per day on days 1, 3, 5
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
One course
References
- Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lübbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol. 2013 Dec 10;31(35):4424-30. Epub 2013 Oct 14. link to original article contains verified protocol PubMed
Induction therapy, older patients or "unfit" patients
7+3i & Panobinostat
back to top |
7+3i: 7 days of cytarabine + 3 days of idarubicin
Regimen
Study | Evidence |
Ocio et al. 2015 (panobidara) | Phase II |
Note that the dose of idarubicin is lower than that used in standard 7+3i. The panobinostat dose is the MTD in this phase Ib/II study.
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 1 to 3
- Panobinostat (Farydak) 10 mg PO once per day on days 8, 10, 12, 15, 17, 19
One course
Non-responders could undergo an identical second cycle. Responders proceeded to receive the same regimen in consolidation (one course), followed by panobinostat maintenance.
References
- Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. link to original article contains verified protocol link to PMC article PubMed
Azacitidine (Vidaza)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Dombret et al. 2015 | Phase III | 7+3d 7+3i Best supportive care Cytarabine |
Might have superior OS |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC once per day on days 1 to 7
28-day cycle for at least 6 cycles
References
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. link to original article contains verified protocol link to PMC article PubMed
Best supportive care
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Kantarjian et al. 2012 | Phase III | Decitabine | Might have inferior OS |
Dombret et al. 2015 | Phase III | Azacitidine | Might have inferior OS |
Amadori et al. 2016 (EORTC/GIMEMA AML-19) | Phase III | Gemtuzumab ozogamicin (Mylotarg) | Inferior OS |
No active antineoplastic treatment, although some trials consider Hydroxyurea (Hydrea) to be a component of best supportive care.
References
- Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. link to original article contains verified protocol link to PMC article PubMed
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. link to original article contains verified protocol link to PMC article PubMed
- Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016 Mar 20;34(9):972-9. Epub 2016 Jan 25. link to original article PubMed
Clofarabine (Clolar)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Faderl et al. 2008 | Randomized Phase II | Clofarabine & Cytarabine | Seems to have inferior EFS |
Burnett et al. 2010 (UWCM-001 and BIOV-121) | Phase II |
Chemotherapy
- Clofarabine (Clolar) 30 mg/m2 IV over one hour once per day on days 1 to 5
One course
A second induction was permitted for SD or better. Responders in Faderl et al. 2008 proceeded to clofarabine & cytarabine consolidation.
References
- Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. link to original article contains verified protocol link to PMC article PubMed
- Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010 May 10;28(14):2389-95. Epub 2010 Apr 12. link to original article PubMed
Clofarabine & Cytarabine
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Faderl et al. 2008 | Randomized Phase II | Clofarabine | Seems to have superior EFS |
Chemotherapy
- Clofarabine (Clolar) 30 mg/m2 IV over one hour once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 20 mg SC once per day on days 1 to 14, given 4 hours after clofarabine on days 1 to 5
One course
A second induction was permitted for SD or better. Responders proceeded to clofarabine & cytarabine consolidation.
Regimen #2
Study | Evidence |
Faderl et al. 2010 | Phase II |
Chemotherapy
- Clofarabine (Clolar) 20 mg/m2 IV once per day on days 1 to 5
- Cytarabine (Cytosar) 20 mg SC BID on days 1 to 10
One course
Patients not achieving CR could undergo an identical second induction after at least 28 days. Patients not achieving CR after the second induction were given salvage decitabine. Patients achieving CR proceeded to consolidation with clofarabine & low-dose cytarabine alternating with decitabine.
References
- Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18. link to original article contains verified protocol link to PMC article PubMed
- Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. link to original article link to PMC article PubMed
- Update: Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. link to original article link to PMC article PubMed
Cytarabine (Cytosar)
back to top |
LoDAC: Low Dose Ara-C (Cytarabine)
LDAC: Low-dose Ara-C (Cytarabine)
Regimen #1, limited duration
Study | Evidence | Comparator | Efficacy |
Sekeres et al. 2012 | Randomized Phase II | LDAC & Lintuzumab | Seems not superior |
Burnett et al. 2013 (UK NCRI AML16) | Phase III | Clofarabine | Seems not superior |
Dennis et al. 2015 | Randomized | LDAC & Vosaroxin | Seems not superior |
Vosaroxin | Seems not superior | ||
Burnett et al. 2015 | Randomized | Sapacitabine | Might have inferior CR rate |
Dombret et al. 2015 | Phase III | Azacitidine | Might have inferior OS |
Chemotherapy
- Cytarabine (Cytosar) 20 mg/m2 SC BID on days 1 to 10
4- to 6-week cycle for up to 4 cycles
Regimen #2, indefinite duration
Study | Evidence | Comparator | Efficacy |
Kantarjian et al. 2012 | Phase III | Decitabine | Might have inferior OS |
Chemotherapy
- Cytarabine (Cytosar) 20 mg/m2 SC once per day on days 1 to 10
4-week cycles until progression or intolerance
References
- Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. link to original article contains verified protocol link to PMC article PubMed
- Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan;98(1):119-28. Epub 2012 Jul 16. link to original article link to PMC article PubMed
- Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK; UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013 Aug 22;122(8):1384-94. Epub 2013 Jul 9. link to original article contains verified protocol PubMed
- Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015 May 7;125(19):2923-32. Epub 2015 Mar 24. link to original article contains verified protocol link to PMC article PubMed
- Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015 Jun;29(6):1312-9. Epub 2015 Feb 13. link to original article contains verified protocol PubMed
- Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9. Epub 2015 May 18. link to original article contains verified protocol link to PMC article PubMed
Cytarabine, Daunorubicin, Sorafenib
back to top |
Regimen
Study | Evidence |
Uy et al. 2017 (CALGB 11001) | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7 (total dose: 700 mg/m2)
- Daunorubicin (Cerubidine) 60 mg/m2 IV once per day on days 1 to 3
- Sorafenib (Nexavar) 400 mg PO BID on days 1 to 7
7-day course
Patients not achieving a hypoplastic marrow on day 14 received re-induction with 5+2 with sorafenib. Patients achieving a CR or CRi proceeded to IDAC & sorafenib consolidation.
References
- Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. Accessed January 26, 2017. link to original article contains verified protocol
Decitabine (Dacogen)
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Issa et al. 2014 | Randomized Phase II | Decitabine & Valproate | Seems not superior |
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 1 hour once per day on days 1 to 5
4- to 6-week cycles
Regimen #2
Study | Evidence | Comparator | Efficacy |
Kantarjian et al. 2012 | Phase III | Cytarabine Best supportive care |
Might have superior OS |
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 1 hour once per day on days 1 to 5
Supportive medications
- Hydroxyurea (Hydrea) could be used up until cycle 1 day 15.
28-day cycles, given until progression of disease or unacceptable toxicity
Regimen #3
Study | Evidence |
Blum et al. 2010 | Phase II |
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 1 hour once per day on days 1 to 10
Supportive medications
- Hydroxyurea (Hydrea) allowed during and prior to cycle 1 in order to maintain WBC count less than 40 x 109/L
28-day cycles
Additional therapy depending on response:
- Patients with persistent AML (greater than or equal to 5% blasts) received repeated cycles with 10 days of decitabine as described above.
- Patients with no morphologic evidence of AML (less than 5% blasts) received 5 days of decitabine as described by decitabine monotherapy maintenance.
References
- Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. link to original article contains verified protocol link to PMC article PubMed
- Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7. Epub 2012 Jun 11. link to original article contains verified protocol link to PMC article PubMed
- Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. link to original article contains verified protocol link to PMC article PubMed
Decitabine & Valproate
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Garcia-Manero et al. 2006 | Phase II | ||
Issa et al. 2014 | Randomized Phase II | Decitabine & Valproate | Seems not superior |
Chemotherapy
- Decitabine (Dacogen) 15 mg/m2 IV over 1 hour once per day on days 1 to 10
- Valproate (Depakote) 50 mg/kg/day (divided in 2 or 3 doses per day) PO on days 1 to 10
28-day cycle for up to 24 total cycles
References
- Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15;108(10):3271-9. Epub 2006 Aug 1. link to original article contains verified protocol link to PMC article PubMed
- Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15;121(4):556-61. Epub 2014 Oct 21. link to original article contains verified protocol link to PMC article PubMed
ICL
back to top |
ICL: Idarubicin, Cytarabine, Lomustine
Regimen
Study | Evidence |
Pigneux et al. 2016 (GOELAMS LAM-SA2002) | Non-randomized portion of RCT |
Chemotherapy
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 1 to 5
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 7
- Lomustine (Ceenu) 200 mg/m2 PO once on day 1
One course
See paper for further details about post-induction therapy
References
- Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. J Clin Oncol. 2017 Feb;35(4):387-393. Epub 2016 Oct 24. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
back to top |
Regimen
Study | Evidence |
Brandwein et al. 2014 | Phase II |
Patient selection was based on MGMT expression by Western blot. See article for details.
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2/day PO on days 1 to 7; complete responders could receive 200 mg/m2/day PO on days 1 to 5
28-day cycle for up to 12 cycles
References
- Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, Galarneau A, Pouliot JF. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol. 2014 Dec;167(5):664-70. Epub 2014 Aug 27. link to original article contains protocol PubMed
Consolidation therapy
CLARA
back to top |
CLARA: CLofarabine and ARA-C (Cytarabine)
Regimen
Study | Evidence | Comparator | Efficacy |
Thomas et al. 2017 | Randomized Phase II | HDAC & G-CSF | Seems to have superior RFS |
Chemotherapy
- Clofarabine (Clolar) 30 mg/m2 IV over 2 hours once per day on days 2 to 6, given first
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 1 to 5, given second, 4 hours after clofarabine, on days 2 to 5
- Filgrastim (Neupogen) 5 mcg/kg IV once per day on days 1 to 6
35-day cycle for 3 cycles
References
- Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol. 2017 Apr 10;35(11):1223-1230. Epub 2017 Feb 21. link to original article contains verified protocol in supplement PubMed
Clofarabine, Idarubicin, and Cytarabine (CIA) Consolidation
Regimen
Study | Evidence |
Nazha et al. 2013 | Phase II |
Treatment preceded by Clofarabine, Idarubicin, and Cytarabine (CIA) Induction.
Chemotherapy
- Clofarabine (Clolar) 15 mg/m2 IV once per day on days 1 to 3
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 1 & 2
- Cytarabine (Cytosar) 750 mg/m2 IV once per day on days 1 to 3
3-day course; repeated every 3 to 4 weeks depending on disease response and recovery from regimen toxicity for up to six cycles
References
- Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. Epub 2013 Sep 9. long link to original article contains verified protocol link to PMC article PubMed
Clofarabine & low-dose Cytarabine alternating with Decitabine
back to top |
Regimen
Study | Evidence |
Faderl et al. 2010 | Phase II |
Treatment preceded by clofarabine & low-dose cytarabine, which is counted as "Cycle 1". Cycles are given every 4 to 7 weeks pending hematologic recovery and resolution of other toxicities.
Clofarabine & low-dose Cytarabine portion
- Clofarabine (Clolar) 20 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Cytosar) 20 mg SC BID on days 1 to 7
Cycles 2, 3, 7 to 9, 13 to 15
Decitabine portion
- Decitabine (Dacogen) 20 mg/m2 IV once per day on days 1 to 5
Cycles 4 to 6, 10 to 12, 16 to 18
References
- Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15;118(18):4471-7. Epub 2012 Jan 26. link to original article contains verified protocol link to PMC article PubMed
- Update: Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15;121(14):2375-82. Epub 2015 Mar 25. link to original article link to PMC article PubMed
Cytarabine & Daunorubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Gardin et al. 2007 (ALFA 9803) | Phase III | 4 + 7 with daunorubicin | Seems to have superior OS |
Ambulatory regimen; treatment preceded by 4 + 7 induction with daunorubicin.
Chemotherapy
- Cytarabine (Cytosar) 60 mg/m2 SC every 12 hours on days 1 to 5 (10 total doses)
- Daunorubicin (Cerubidine) 45 mg/m2 IV once on day 1
1-month cycle for up to 6 cycles
References
- Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007 Jun 15;109(12):5129-35. Epub 2007 Mar 6. link to original article contains verified protocol PubMed
Cytarabine & Idarubicin
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Gardin et al. 2007 (ALFA 9803) | Phase III | 4 + 7 with idarubicin | Seems to have superior OS |
Ambulatory regimen; treatment preceded by 4 + 7 induction with idarubicin.
Chemotherapy
- Cytarabine (Cytosar) 60 mg/m2 SC every 12 hours on days 1 to 5 (10 total doses)
- Idarubicin (Idamycin) 9 mg/m2 IV once on day 1
1-month cycle for up to 6 cycles
References
- Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007 Jun 15;109(12):5129-35. Epub 2007 Mar 6. link to original article contains verified protocol PubMed
Cytarabine & Midostaurin
Cytarabine & Midostaurin consolidation therapy for acute myeloid leukemia (AML)
Cytarabine, Idarubicin, Sorafenib
back to top |
Regimen
Study | Evidence |
Ravandi et al. 2010 | Phase I/II |
Treatment preceded by cytarabine, idarubicin, sorafenib induction. Regimen details are from the phase II part of the published phase I/II trial.
Chemotherapy
- Cytarabine (Cytosar) 750 mg/m2/day IV continuous infusion on days 1 to 3 (total dose: 2250 mg/m2)
- Idarubicin (Idamycin) 8 mg/m2 IV over 1 hour once per day on days 1 & 2
- Sorafenib (Nexavar) 400 mg PO BID "for up to 28 days"
4 to 6-week cycle for up to 5 cycles
Treatment followed by sorafenib maintenance.
References
- Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. link to original article contains verified protocol link to PMC article PubMed
- Update: Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. link to original article link to PMC article PubMed
Cytarabine, Idarubicin, Vorinostat
back to top |
Regimen
Study | Evidence |
Garcia-Manero et al. 2012 | Phase II |
Treatment preceded by Cytarabine, Idarubicin, Vorinostat induction therapy.
Chemotherapy
- Cytarabine (Cytosar) 750 mg/m2/day IV continuous infusion on days 4 to 6 (total dose: 2250 mg/m2)
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 4 & 5
- Vorinostat (Zolinza) 500 mg PO TID on days 1 to 3
Supportive medications
- Methylprednisolone (Solumedrol) (note: the paper spelled this as "salumedrol"--it's assumed this is what they meant) 50 mg IV on days of Cytarabine (Cytosar) to prevent fever and rash
6-day course for up to 5 cycles
To be followed by Vorinostat (Zolinza) maintenance therapy.
References
- Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
Etoposide & Mitoxantrone
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Vellenga et al. 2011 (HOVON-SAKK AML-29/AML-42) | Phase III | Bu/Cy -> autoHCT | Might have inferior RFS |
Treatment preceded by 7+3i -> amsacrine & cytarabine.
Chemotherapy
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 5
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 5
References
- Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).; Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011 Dec 1;118(23):6037-42. Epub 2011 Sep 27. link to original article contains verified protocol PubMed
HAM
back to top |
HAM: High-dose Ara-C (Cytarabine), Mitoxantrone
Regimen
Study | Evidence |
Wierzbowksa et al. 2008 (PALG) | Phase II |
Holowiecki et al. 2012 (PALG AML1/2004) | Non-randomized portion of RCT |
Treatment in Wierzbowska et al. 2007 preceded by CLAG-M. Treatment in PALG AML1/2004 preceded by DA versus DAC versus DAF.
Chemotherapy
- Cytarabine (Cytosar) 1500 mg/m2 IV once per day on days 1 to 3
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 3 to 5
Followed by HiDAC consolidation.
References
- Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Holowiecki J, Kyrcz-Krzemien S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kielbinski M, Zawilska K, Kloczko J, Wrzesien-Kus A; Polish Adult Leukemia Group. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008 Feb;80(2):115-26. Epub 2007 Dec 11. link to original article contains verified protocol PubMed content property of HemOnc.org
- Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. link to original article contains verified protocol PubMed
HDAC & G-CSF
back to top |
HDAC: High Dose Ara-C (Cytarabine)
Regimen
Study | Evidence | Comparator | Efficacy |
Thomas et al. 2017 | Randomized Phase II | CLARA | Seems to have inferior RFS |
Chemotherapy
- Cytarabine (Cytosar) 3000 mg/m2 IV over 3 hours Q12H on days 1, 3, 5 (6 total doses)
- Filgrastim (Neupogen) 5 mcg/kg IV once per day on days 1 to 5
35-day cycle for 3 cycles
References
- Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol. 2017 Apr 10;35(11):1223-1230. Epub 2017 Feb 21. link to original article contains verified protocol in supplement PubMed
HiDAC/HDAC
back to top |
HiDAC: High Dose Ara-C (Cytarabine)
HDAC: High Dose Ara-C (Cytarabine)
Regimen #1
Study | Evidence | Comparator | Efficacy |
Mayer et al. 1994 | Phase III | Low-dose continuous infusion cytarabine | Seems to have superior OS |
Röllig et al. 2015 (SORAML) | Randomized Phase II | HiDAC & Sorafenib | Seems to have inferior EFS |
Chemotherapy
- Cytarabine (Cytosar) 3000 mg/m2 IV over 3 hours Q12H on days 1, 3, 5 (6 total doses)
28-day (minimum) cycle or 1 week after marrow recovery, whichever comes later
Patients in Mayer et al. 1994 received up to 4 cycles. Patients in SORAML received 3 cycles.
Regimen #2
Study | Evidence | Comparator | Efficacy |
Fukushima et al. 2012 | Randomized, <20 pts in this arm | mIDAC | Seems not superior |
Treatment preceded by BHAC-MMV.
Chemotherapy
- Cytarabine (Cytosar) 2000 mg/m2 IV over 1 hour Q12H on days 1 to 5 (10 total doses)
Two cycles
Treatment followed by A-VVV.
Regimen #3
Study | Evidence |
Holowiecki et al. 2012 | Non-randomized |
Treatment preceded by cytarabine & mitoxantrone consolidation. Details in the text are scant.
Chemotherapy
- Cytarabine (Cytosar) 2000 mg/m2 IV Q12H on days 1, 3, 5 (6 total doses)
References
- Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903. link to original article contains verified protocol PubMed
- Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 1;105(9):3420-7. Epub 2004 Nov 30. link to original article link to PMC article PubMed
- Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011 Feb 24;117(8):2366-72. Epub 2010 Dec 29. link to original article PubMed
- Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011 Aug 18;118(7):1754-62. Epub 2011 Jun 20. link to original article PubMed
- Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012 Feb;32(2):643-7. link to original article contains verified protocol PubMed
- Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013 Jun 10;31(17):2094-102. Epub 2013 Apr 29. link to original article PubMed
- Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10;33(11):1252-7. Epub 2015 Mar 2. link to original article contains verified protocol PubMed
- Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of Clinical Oncology. 2012 Jul 10;30(20):2441-8. Epub 2012 Apr 16. link to original article contains verified protocol PubMed
- Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015 Dec;16(16):1691-9. Epub 2015 Nov 6. link to original article contains protocol PubMed
IDAC/mIDAC
back to top |
IDAC: Intermediate Dose Ara-C (Cytarabine)
mIDAC: modified Intermediate Dose Ara-C (Cytarabine)
Regimen #1
Study | Evidence | Comparator | Efficacy |
Fukushima et al. 2012 | Randomized, <20 pts in this arm | HDAC | Seems not superior |
Treatment preceded by BHAC-MMV.
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV over 1 hour Q12H on days 1 to 5 (10 total doses)
Two cycles
Treatment followed by A-VVV.
Regimen #2
Study | Evidence |
Stone et al. 2015 | Phase II |
Treatment preceded by 7+3d.
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV over 3 hours once per day on days 1, 3, 5 (3 total doses)
References
- Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012 Feb;32(2):643-7. link to original article contains verified protocol PubMed
- Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. J Clin Oncol. 2015 Apr 10;33(11):1252-7. Epub 2015 Mar 2. link to original article contains verified protocol PubMed
IDAC & Sorafenib
back to top |
IDAC: Intermediate Dose Ara-C (Cytarabine)
Regimen
Study | Evidence |
Uy et al. 2017 (CALGB 11001) | Phase II |
Treatment preceded by 7+3 with sorafenib induction.
Chemotherapy
- Cytarabine (Cytosar) 2000 mg/m2 IV over 3 hours once per day on days 1 to 5
- Sorafenib (Nexavar) 400 mg PO BID for 28 days
Two cycles
Treatment followed by sorafenib maintenance.
References
- Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. Accessed January 26, 2017. link to original article contains verified protocol
Maintenance therapy
Azacitidine (Vidaza)
back to top |
Regimen #1
Study | Evidence |
Nand et al. 2013 | Phase II |
Treatment preceded by azacitidine and gemtuzumab ozogamicin consolidation.
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC once on day 1
28-day cycle for 4 cycles
Regimen #2
Study | Evidence |
Grövdal et al. 2010 | Phase II |
Intended to be used for transformed MDS patients in remission after AML induction therapy.
Chemotherapy
- Azacitidine (Vidaza) 60 mg/m2 SC once per day on days 1 to 5
28-day cycles
References
- Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. link to original article contains verified protocol PubMed
- Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013 Nov 14;122(20):3432-9. Epub 2013 Oct 3. link to original article contains verified protocol link to PMC article PubMed
Decitabine (Dacogen)
back to top |
Regimen
Study | Evidence |
Blum et al. 2010 | Phase II |
Treatment preceded by decitabine monotherapy induction.
Blum et al. 2010 did not clearly state whether decitabine maintenance is at the same dosage/frequency as induction therapy. This is the inferred dosage from the paper.
Chemotherapy
- Decitabine (Dacogen) 20 mg/m2 IV over 1 hour once per day on days 1 to 5
- Patients with no evidence of residual disease by flow cytometry or cytogenetics who had grade 4 neutropenia (ANC less than 500/uL) persisting greater than or equal to 14 days received 4 days instead of 5 days of decitabine starting with the following cycle. If neutropenia occurred again as above with 4 days of decitabine, patients received 3 days instead of 4 days of decitabine starting with the following cycle.
28-day cycles, given until relapsed disease or unacceptable toxicity
References
- Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. link to original article contains verified protocol link to PMC article PubMed
LoDAC/LDAC
back to top |
LoDAC: Low Dose Ara-C (cytarabine)
LDAC: Low Dose Ara-C (cytarabine)
Regimen
Study | Evidence | Comparator | Efficacy |
Robles et al. 2000 (ECOG E5483) | Phase III | Observation | Might have superior DFS |
Chemotherapy
- Cytarabine (Cytosar) 10 mg/m2 SC BID on days 1 to 21
2-month cycles, continue until relapse
References
- Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 2000 Aug;14(8):1349-53. contains protocol PubMed
Midostaurin (Rydapt)
Midostaurin (Rydapt) maintenance therapy for acute myeloid leukemia (AML)
Observation
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Robles et al. 2000 (ECOG E5483) | Phase III | LoDAC | Might have inferior DFS |
No further antineoplastic treatment; included here because it was used as a comparator arm in this setting.
References
- Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 2000 Aug;14(8):1349-53. contains protocol PubMed
Panobinostat (Farydak)
back to top |
7+3i: 7 days of cytarabine + 3 days of idarubicin
Regimen
Study | Evidence |
Ocio et al. 2015 (panobidara) | Phase Ib/II |
Treatment preceded by 7+3i & panobinostat x 2 to 3 cycles. The panobinostat dose is the MTD in this phase Ib/II study.
Chemotherapy
- Panobinostat (Farydak) as follows:
- Odd weeks: 40 mg PO once per day three days of the week
- Even weeks: no treatment
Continued until progression or intolerance
References
- Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300. Epub 2015 Jul 9. link to original article contains verified protocol link to PMC article PubMed
Sorafenib (Nexavar)
back to top |
Regimen
Study | Evidence |
Ravandi et al. 2010 | Phase I/II |
Uy et al. 2017 (CALGB 11001) | Phase II |
Treatment in Ravandi et al. 2010 preceded by cytarabine, idarubicin, and sorafenib consolidation; regimen details are from the phase II part of the published phase I/II trial. Treatment in CALGB 11001 preceded by IDAC & sorafenib consolidation.
Chemotherapy
- Sorafenib (Nexavar) 400 mg PO BID
Varied duration, as follows:
- Ravandi et al 2010: Up to one year of sorafenib therapy, including consolidation course(s)
- CALGB 11001: 28-day cycle for up to 12 cycles
References
- Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856-62. Epub 2010 Mar 8. link to original article contains verified protocol link to PMC article PubMed
- Update: Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul;28(7):1543-5. Epub 2014 Feb 3. link to original article link to PMC article PubMed
- Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. Accessed January 26, 2017. link to original article contains verified protocol
Vorinostat (Zolinza)
back to top |
Regimen
Study | Evidence |
Garcia-Manero et al. 2012 | Phase II |
Treatment preceded by cytarabine, idarubicin, and vorinostat consolidation.
Chemotherapy
- Vorinostat (Zolinza) 200 mg PO TID on days 1 to 14
28-day cycle for up to 12 cycles
References
- Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20;30(18):2204-10. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
Relapsed/refractory
5+2d
back to top |
Regimen
Study | Evidence |
Zeidner et al. 2015 | Non-randomized |
Treatment preceded by 7+3d (high-dose).
Chemotherapy
- Cytarabine (Cytosar) 100 mg/m2/day IV continuous infusion on days 1 to 5 (total dose: 500 mg/m2)
- Daunorubicin (Cerubidine) 45 mg/m2 IV once per day on days 1 to 3
5-day course
References
- Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed
ADE
back to top |
ADE: Ara-C (Cytarabine), Daunorubicin, Etoposide
Regimen
Study | Evidence | Comparator | Efficacy |
Milligan et al. 2006 (MRC AML-HR) | Phase III | FLA | Seems to have superior OS |
Course 1
- Cytarabine (Cytosar) 100 mg/m2 IV push Q12H on days 1 to 10 (20 total doses)
- Daunorubicin (Cerubidine) 50 mg/m2 IV slow push once per day on days 1, 3, 5
- Etoposide (Vepesid) 100 mg/m2 IV over 1 hour once per day on days 1 to 5
Course 2
- Cytarabine (Cytosar) 100 mg/m2 IV push Q12H on days 1 to 8 (16 total doses)
- Daunorubicin (Cerubidine) 50 mg/m2 IV slow push once per day on days 1, 3, 5
- Etoposide (Vepesid) 100 mg/m2 IV over 1 hour once per day on days 1 to 5
References
- Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK; NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006 Jun 15;107(12):4614-22. Epub 2006 Feb 16. link to original article PubMed
Azacitidine (Vidaza)
back to top |
Regimen
Study | Evidence |
Thepot et al. 2010 | Phase II |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC once per day on days 1 to 7
28-day cycle for at least 4 to 6 cycles
References
- Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010 Nov 11;116(19):3735-42. Epub 2010 Jul 27. link to original article PubMed
Azacitidine & Sorafenib
back to top |
Regimen
Study | Evidence |
Ravandi et al. 2013 | Phase II |
Majority of patients in the phase II trial were FLT-3 ITD positive
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC or IV once per day on days 1 to 7
- Sorafenib (Nexavar) 400 mg PO BID
Supportive medications
- "All patients received antimicrobials, supportive care, and transfusions of blood products according to the institutional guidelines."
4 to 8 week cycles at treating physician's discretion
References
- Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 6;121(23):4655-62. Epub 2013 Apr 23. link to original article contains verified protocol link to PMC article PubMed
Cladribine (Leustatin)
back to top |
Regimen
Study | Evidence |
Santana et al. 1992 | Phase II |
Chemotherapy
- Cladribine (Leustatin) 8.9 mg/m2/day IV continuous infusion on days 1 to 5 (total dose: 44.5 mg/m2)
References
- Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar;10(3):364-70. link to original article PubMed
CLAG
back to top |
CLAG: CLadribine, Ara-C (Cytarabine), G-CSF
Regimen
Study | Evidence |
Robak et al. 2000 | Phase II |
Chemotherapy
- Cladribine (Leustatin) 5 mg/m2 IV over 2 hours once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 1 to 5, given second, 2 hours after Cladribine (Leustatin)
- Filgrastim (Neupogen) 300 mcg SC once per day on days -1 to 5; first dose is given 24 hours before first dose of Cladribine (Leustatin)
References
- Robak T, Wrzesien'-Kus' A, Lech-Maran'da E, Kowal M, Dmoszyn'ska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000 Sep;39(1-2):121-9. link to original article contains verified protocol PubMed
- Retrospective: Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009 Aug;9(4):298-301. PubMed
CLAG-M, CLAM
back to top |
CLAG-M: CLadribine, Ara-C (Cytarabine), G-CSF, Mitoxantrone
Regimen
Study | Evidence |
Wierzbowksa et al. 2008 (PALG) | Phase II |
All patients enrolled in this study had received first-line DA, DAC, or DAF.
Chemotherapy
- Cladribine (Leustatin) 5 mg/m2 IV over 2 hours once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine
- Filgrastim (Neupogen) based on WBC count:
- WBC count less than or equal to 20 x 109/L: 300 mcg SC once per day on days 0 to 5; first dose is given 24 hours prior to chemotherapy
- WBC count greater than 20 x 109/L: 300 mcg SC once per day on days 1 to 5, commenced simultaneously to cladribine
- Mitoxantrone (Novantrone) 10 mg/m2 IV once per day on days 1 to 3
Patients with PR were recommended to undergo a second course of CLAG-M. Primary refractory patients achieving CR after 2nd CLAG-M proceeded to HAM consolidation. Others could receive another course of CLAG-M or HAM consolidation per investigator discretion.
References
- Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Holowiecki J, Kyrcz-Krzemien S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kielbinski M, Zawilska K, Kloczko J, Wrzesien-Kus A; Polish Adult Leukemia Group. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008 Feb;80(2):115-26. Epub 2007 Dec 11. link to original article contains verified protocol PubMed content property of HemOnc.org
- Retrospective: Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009 Aug;9(4):298-301. PubMed
Clofarabine (Clolar)
back to top |
Regimen
Study | Evidence |
Kantarjian et al. 2003 | Phase II |
Chemotherapy
- Clofarabine (Clolar) 40 mg/m2 IV over 1 hour once per day on days 1 to 5
3- to 6-week cycles
References
- Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 1;102(7):2379-86. Epub 2003 Jun 5. link to original article contains verified protocol PubMed
Clofarabine & Cytarabine
back to top |
Regimen #1
Study | Evidence | Comparator | Efficacy |
Faderl et al. 2012 (CLASSIC I) | Phase III | Cytarabine | Superior EFS |
Chemotherapy
- Clofarabine (Clolar) 40 mg/m2 IV over 1 hour once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 1 to 5, given second, 3 hours after completion of clofarabine infusion
Supportive medications
- "The use of prophylactic antibacterial, antifungal, and antiviral agents was recommended according to institutional guidelines."
1 to 3 cycles
It was not clear if the consolidation cycle mentioned here would also be clofarabine and cytarabine or something else: "Patients who achieved remission after their induction cycle could receive a single (optional) consolidation cycle; patients who did not achieve remission after induction but who demonstrated hematologic improvement could receive a reinduction cycle followed by a single (optional) consolidation cycle."
Regimen #2
Study | Evidence |
Middeke et al. 2015 (BRIDGE) | Phase II |
Chemotherapy
- Clofarabine (Clolar) 30 mg/m2 IV once per day on days 1 to 5
- Cytarabine (Cytosar) 1000 mg/m2 IV once per day on days 1 to 5
At least one cycle
Chemo-responsive patients proceeded to clofarabine & melphalan -> allogeneic SCT.
Regimen #3, Clofarabine & LDAC
Study | Evidence |
Buckley et al. 2015 | Phase I/II |
LDAC: Low-Dose Ara-C (Cytarabine)
The dose of clofarabine is the one reported as the MTD. Note that the doses of both drugs are much lower than the other variants here.
Chemotherapy
- Clofarabine (Clolar) 20 mg PO once per day on days 1 to 5
- Cytarabine (Cytosar) as follows (per physician choice):
- 20 mg/m2 SC BID on days 1 to 10
- 20 mg/m2 SC once per day on days 1 to 14
Cycle duration not explicitly defined; presumably 28 days
Regimen #4
Study | Evidence |
Agura et al. 2011 | Phase II |
Chemotherapy
- Clofarabine (Clolar) 40 mg/m2 IV over 1 hour once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 1 to 5, given second, 4 hours after completion of clofarabine infusion
Supportive medications
- Dexamethasone (Decadron) 10 mg IV once per day
- 5-HT3 antagonists on each day of chemotherapy
- Hydration at 150 mL/m2/H "to prevent tumor lysis syndrome" during chemotherapy
- Bumetanide (Bumex) 2 to 4 mg IV push once to twice per day as needed to keep weight within 1 kg of patient's initial weight
- Levofloxacin (Levaquin) 500 mg PO/IV once per day
- Acyclovir (Zovirax) 500 mg IV Q12H
- One of the following antifungals:
- Caspofungin (Cancidas) 50 mg IV once per day
- Voriconazole (Vfend) 200 mg (route not specified) BID
- Parenteral nutrition allowed
- No routine use of growth factors
Up to 4 total cycles; subsequent cycles start after hematologic recovery from the previous cycle and were recommended for patients who had hematologic response, but not complete response (CR)
References
- Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1;105(3):940-7. Epub 2004 Oct 14. link to original article PubMed
- Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C, Li S, Saracino G, Tadic-Ovcina M, Fay J. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist. 2011;16(2):197-206. Epub 2011 Jan 27. link to original article contains verified protocol link to PMC article PubMed
- Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
- Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. Br J Haematol. 2015 Aug;170(3):349-55. Epub 2015 Apr 8. link to original article contains verified protocol PubMed
- Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. Epub 2015 Aug 18. link to original article contains protocol PubMed
Cytarabine (Cytosar)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Faderl, et al. 2012 (CLASSIC I) | Phase III | Clofarabine & Cytarabine | Inferior EFS |
Ravandi et al. 2015 (VALOR) | Phase III | Cytarabine & Vosaroxin | Might have inferior OS |
Note: In CLASSIC I, it was not clear if the consolidation cycle mentioned here would also be cytarabine or something else: "Patients who achieved remission after their induction cycle could receive a single (optional) consolidation cycle; patients who did not achieve remission after induction but who demonstrated hematologic improvement could receive a reinduction cycle followed by a single (optional) consolidation cycle." In VALOR, the total duration of treatment is not specified.
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV over 2 hours once per day on days 1 to 5
Supportive medications
- "The use of prophylactic antibacterial, antifungal, and antiviral agents was recommended according to institutional guidelines."
1 to 3 cycles (see note)
References
- Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. Epub 2012 May 14. link to original article contains verified protocol link to PMC article PubMed
- Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep;16(9):1025-36. Epub 2015 Jul 30.link to original article contains protocol link to PMC article PubMed
Cytarabine & Mitoxantrone
back to top |
Regimen
Study | Evidence |
Sternberg et al. 2000 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 500 mg/m2 IV over 90 minutes every 12 hours on days 1 to 6 (12 total doses)
- Mitoxantrone (Novantrone) 5 mg/m2 IV bolus once per day on days 1 to 5
References
- Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer. 2000 May 1;88(9):2037-41. link to original article contains verified protocol PubMed
Etoposide & Mitoxantrone
back to top |
Regimen
Study | Evidence |
Ho et al. 1988 | Phase II |
Chemotherapy
- Etoposide (Vepesid) 100 mg/m2 IV over 30 minutes once per day on days 1 to 5
- Mitoxantrone (Novantrone) 10 mg/m2 IV over 15 minutes once per day on days 1 to 5
References
- Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. J Clin Oncol. 1988 Feb;6(2):213-7. link to original article PubMed
FLAG
back to top |
FLAG: FLudarabine, Ara-C (Cytarabine), G-CSF
Regimen
Study | Evidence |
Montillo et al. 1998 | Phase II |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV over 30 minutes once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 1 to 5, given second, 4 hours after the start of Fludarabine (Fludara)
- Filgrastim (Neupogen) or Lenograstim (Granocyte) 5 mcg/kg SC once per day starting on day -1 (the paper described this as "day 0"), first dose given 24 hours before first dose of chemotherapy, to continue until neutrophil recovery
References
- Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998 Jun;58(2):105-9. link to original article contains verified protocol PubMed
FLAG-IDA
back to top |
FLAG-IDA: FLudarabine, Ara-C (Cytarabine), G-CSF (Filgrastim), IDArubicin
Regimen
Study | Evidence |
Parker et al. 1997 | Phase II, <20 patients |
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV over 30 minutes once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 1 to 5, given second, 4 hours after Fludarabine (Fludara)
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting on day 6, to continue until neutrophil recovery
- Idarubicin (Idamycin) 10 mg/m2 IV once per day on days 1 to 3
References
- Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997 Dec;99(4):939-44. PubMed
- Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003 Apr;82(4):231-5. Epub 2003 Mar 15. link to original article PubMed
F-SHAI
back to top |
F-SHAI: Fludarabine, Sequential High-dose Ara-C (cytarabine), Idarubicin
Regimen
Study | Evidence | Comparator | Efficacy |
Fiegl et al. 2013 | Phase III | SHAI | Seems to have superior TTTF |
Unclear from the abstract how many doses of fludarabine to be given.
Chemotherapy
- Fludarabine (Fludara) 15 mg/m2 IV 4 hours prior to Cytarabine (Cytosar)
- Cytarabine (Cytosar) 1000 mg/m2 IV BID on days 1, 2, 8, 9
- Dose increased to 3000 mg/m2 for patients 60 or younger with refractory AML or greater than or equal to 2nd relapse
- Idarubicin (Idamycin) 10? mg/m2 IV once per day on days 3, 4, 10, 11
One course
References
- Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia. 2014 May;28(5):1001-7. Epub 2013 Oct 22. link to original article contains protocol PubMed
GCLAC
back to top |
GCLAC: G-csf, Clofarabine, Ara-C
Regimen
Study | Evidence |
Becker et al. 2011 | Phase II |
Chemotherapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting day -1, continuing until ANC at least 2000/uL for 2 consecutive days
- Clofarabine (Clolar) 25 mg/m2 IV over 1 hour once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 2000 mg/m2 IV over 4 hours once per day on days 1 to 5, given second, 4 hours after start of Clofarabine (Clolar) infusion
One course with one re-induction allowed for patients with greater than 5% blasts at day 21 Patients achieving CR could receive induction with clofarabine reduced to 20 mg/m2, and cytarabine reduced to 1000 mg/m2, up to 2 cycles.
References
- Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011 Oct;155(2):182-9. Epub 2011 Aug 18. link to original article contains verified protocol link to PMC article PubMed
IAP
back to top |
IAP: Idarubicin, Ara-C (cytarabine), Pravastatin
Regimen
Study | Evidence |
Advani et al. 2014 (SWOG S0919) | Phase II |
Chemotherapy
- Idarubicin (Idamycin) 12 mg/m2 IV once per day on days 4 to 6
- Cytarabine (Cytosar) 1500 mg/m2 IV once per day on days 4 to 7
- Pravastatin (Pravachol) 1280 mg PO once per day on days 1 to 8
Patients achieving a CR could receive 2 cycles of consolidation
References
- Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol. 2014 Oct;167(2):233-7. Epub 2014 Jul 18. link to original article link to PMC article PubMed
MEC
back to top |
MEC: Mitoxantrone, Etoposide, Cytarabine
Regimen #1
Study | Evidence | Comparator | Efficacy |
Feldman et al. 2005 | Phase III | MEC & Lintuzumab | Seems not superior |
Chemotherapy
- Mitoxantrone (Novantrone) 8 mg/m2 IV once per day on days 1 to 6
- Etoposide (Vepesid) 80 mg/m2 IV once per day on days 1 to 6
- Cytarabine (Cytosar) 1000 mg/m2 IV once per day on days 1 to 6
Regimen #2
Study | Evidence |
Amadori et al. 1991 | Phase II |
Chemotherapy
- Mitoxantrone (Novantrone) 6 mg/m2 IV bolus once per day on days 1 to 6
- Etoposide (Vepesid) 80 mg/m2 IV over 1 hour once per day on days 1 to 6
- Cytarabine (Cytosar) 1000 mg/m2 IV over 6 hours once per day on days 1 to 6
Regimen #3
Study | Evidence |
Kohrt et al. 2010 | Retrospective |
Chemotherapy
- Mitoxantrone (Novantrone) 8 mg/m2 IV push once per day on days 1 to 5, given third
- Etoposide (Vepesid) 100 mg/m2 IV over 2 hours once per day on days 1 to 5, given first
- Cytarabine (Cytosar) 1000 mg/m2 IV once per day on days 1 to 5, given second
References
- Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991 Jul;9(7):1210-4. link to original article PubMed
- Retrospective: Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010 Nov;85(11):877-81. link to original article contains verified protocol PubMed
- Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6. link to original article contains verified protocol PubMed
Ruxolitinib (Jakafi)
back to top |
Regimen
Study | Evidence |
Eghtedar et al. 2012 | Phase II |
Chemotherapy
- Ruxolitinib (Jakafi) 25 mg PO BID
28-day cycles
Patients with progression were allowed to increase the dose to 50 mg PO BID
References
- Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614-8. Epub 2012 Mar 15. link to original article contains verified protocol link to PMC article PubMed
SHAI
back to top |
SHAI: Sequential High-dose Ara-C (Cytarabine), Idarubicin
Regimen
Study | Evidence | Comparator | Efficacy |
Fiegl et al. 2013 | Phase III | F-SHAI | Seems to have inferior TTTF |
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV BID on days 1, 2, 8, 9
- Dose increased to 3000 mg/m2 for patients 60 or younger with refractory AML or greater than or equal to 2nd relapse
- Idarubicin (Idamycin) 10?mg/m2 IV once per day on days 3, 4, 10, 11
One course
References
- Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia. 2014 May;28(5):1001-7. Epub 2013 Oct 22. link to original article contains protocol PubMed
Response criteria
NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia (1990)
- Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990 May;8(5):813-9. Review. link to original article PubMed
Revised International Working Group recommendations (2003)
- Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco]. link to original article PubMed
Prognosis
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse (2005)
back to top |
- Relapse-free interval from first complete remission
- Greater than 18 months (0 points)
- 7 to 18 months (3 points)
- Less than or equal to 6 months (5 points)
- Cytogenetics at diagnosis
- t(16;16) or inv(16) with or without additional cytogenetic abnormalities (0 points)
- t(8;21) with or without additional cytogenetic abnormalities (3 points)
- Normal, intermediate, unfavorable, or unknown cytogenetics (5 points)
- Age at time of first relapse
- Less than or equal to 35 years (0 points)
- 36 to 45 years (1 point)
- Greater than 45 years (2 points)
- Stem cell transplantation performed before first relapse
- No (0 points)
- Yes, autologous or allogeneic (2 points)
Risk stratification:
- 1 to 6 points: Favorable risk (1-year OS of 70%; 5-year OS of 46%)
- 7 to 9 points: Intermediate risk (1-year OS of 49%; 5-year OS of 18%)
- 10 to 14 points: Poor risk (1-year OS of 16%; 5-year OS of 4%)
References
- Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Löwenberg B. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005 Mar 20;23(9):1969-78. Epub 2005 Jan 4. link to original article PubMed
Prognosis in cytogenetically normal AML
- Seminal paper comparing the mutational status of NPM1, FLT3, CEBPA, MLL, and NRAS with clinical outcome: Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 1;358(18):1909-18. link to original article PubMed
Investigational agents
These are drugs under study with at least some promising results for this disease.
Additional information
Antifungal prophylaxis
- Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood. 2015 Dec 24;126(26):2790-7. Epub 2015 Oct 26. Review. link to original article link to PMC article PubMed